Oral drug combo tested for aggressive blood disease
NCT ID NCT05918055
Summary
This early-phase trial tested a new combination of two oral drugs, eltanexor and Inqovi, for adults with high-risk myelodysplastic syndromes (MDS), a serious bone marrow disorder that can lead to leukemia. The study aimed to find a safe, effective dose and see if the combo could control the disease in patients whose prior treatments had failed. The trial was terminated early after enrolling only 3 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.